AxoGen (NASDAQ:AXGN) Posts Quarterly Earnings Results, Misses Estimates By $0.03 EPS

AxoGen (NASDAQ:AXGN) announced its quarterly earnings results on Tuesday. The medical equipment provider reported $0.01 earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.03), Zacks reports. AxoGen had a negative return on equity of 14.91% and a negative net margin of 7.91%. AxoGen updated its FY 2025 guidance to EPS.

AxoGen Price Performance

Shares of AXGN stock opened at $18.01 on Tuesday. The firm has a fifty day simple moving average of $17.36 and a 200-day simple moving average of $14.87. AxoGen has a twelve month low of $5.55 and a twelve month high of $19.19. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.47 and a current ratio of 3.74.

Analyst Ratings Changes

Separately, Canaccord Genuity Group upped their target price on AxoGen from $18.00 to $22.00 and gave the stock a “buy” rating in a research report on Monday, February 3rd.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.